Phase II Trial Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma.

Trial Profile

Phase II Trial Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Apr 2017

At a glance

  • Drugs Ofatumumab (Primary)
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Apr 2014 Status changed from active, no longer recruiting to completed.
    • 06 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 15 Nov 2011 Actual initiation date changed from 1 Jan 2011 to 1 Nov 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top